Drug Profile
Dronabinol - GW Pharmaceuticals
Alternative Names: GW-2000-02; Tetrahydrocannabinol - GW Pharmaceuticals; THC - GW PharmaceuticalsLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator GW Pharmaceuticals
- Class Antidementias; Antiemetics; Antineoplastics; Appetite stimulants; Cannabinoids; Chromans; Muscle relaxants; Non-opioid analgesics; Small molecules
- Mechanism of Action Cannabinoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Neuropathic pain; Pain; Postoperative pain
Most Recent Events
- 05 May 2021 GW Pharmaceuticals has been acquired by Jazz Pharmaceuticals plc
- 26 Aug 2009 No development reported - Phase-II for Postoperative pain in United Kingdom (Buccal)
- 26 Aug 2009 No development reported - Preclinical for Pain in United Kingdom (Buccal)